Neurogene Inc. SEC filings NGNE
Neurogene Inc. has 750 filings in SEC EDGAR's recent list, going back to Jun 25, 2007. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 4, 2025 | — |
| CORRESP | Letter to the SEC | Apr 2, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2025 | — |
| EFFECT | Filing | Mar 28, 2025 | — |
| EFFECT | Filing | Dec 16, 2024 | — |
| CORRESP | Letter to the SEC | Dec 12, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2024 | — |
| NT 10-Q | Filing | Nov 14, 2024 | Sep 30, 2024 |
| 425 | Filing | Dec 6, 2023 | — |
| 425 | Filing | Dec 4, 2023 | — |
| 425 | Filing | Nov 30, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 13, 2023 | — |
| EFFECT | Filing | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 8, 2023 | — |
| CORRESP | Letter to the SEC | Nov 8, 2023 | — |
| CORRESP | Letter to the SEC | Oct 18, 2023 | — |
| SEC STAFF LETTER | Filing | Oct 10, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2023 | — |
| 425 | Filing | Oct 5, 2023 | — |
| CORRESP | Letter to the SEC | Sep 28, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2023 | — |
| 425 | Filing | Jul 18, 2023 | — |
| 425 | Filing | Jul 18, 2023 | — |
| EFFECT | Filing | May 18, 2022 | — |
| CORRESP | Letter to the SEC | May 16, 2022 | — |
| UPLOAD | Letter from the SEC | May 13, 2022 | — |
| EFFECT | Filing | Dec 21, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2020 | — |
| CT ORDER | Filing | Aug 31, 2018 | — |
| EFFECT | Filing | Apr 6, 2018 | — |
| CORRESP | Letter to the SEC | Apr 4, 2018 | — |
| EFFECT | Filing | Jan 19, 2017 | — |
| CORRESP | Letter to the SEC | Jan 17, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 17, 2017 | — |
| EFFECT | Filing | Jan 26, 2016 | — |
| CORRESP | Letter to the SEC | Jan 21, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2015 | — |
| EFFECT | Filing | Apr 9, 2015 | — |
| POS EX | Filing | Mar 7, 2014 | — |
| EFFECT | Filing | Mar 6, 2014 | — |
| CT ORDER | Filing | Mar 6, 2014 | — |
| CERTNAS | Auto-generated paper document | Mar 4, 2014 | — |
| CORRESP | Letter to the SEC | Mar 4, 2014 | — |
| CORRESP | Letter to the SEC | Mar 4, 2014 | — |
| 8-A12B | Filing | Mar 3, 2014 | — |
| CORRESP | Letter to the SEC | Jan 28, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2014 | — |
| DRSLTR | Filing | Dec 24, 2013 | — |
| DRS/A | Filing | Dec 24, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2013 | — |
| DRS | Filing | Nov 18, 2013 | — |
| D | Filing | Apr 1, 2013 | — |
| D | Filing | Sep 26, 2011 | — |
| D | Filing | Feb 11, 2011 | — |
| D | Filing | Jun 25, 2010 | — |
| D | Filing | Apr 15, 2010 | — |
| REGDEX/A | Auto-generated paper document | Mar 13, 2009 | — |
| REGDEX | Auto-generated paper document | Feb 28, 2008 | — |
| REGDEX | Auto-generated paper document | Jun 25, 2007 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc. (until Dec 6, 2023); AQUINOX PHARMACEUTICALS, INC (until Aug 12, 2019); AQUINOX PHARMACEUTICALS (USA) INC (until Dec 24, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.